The Beigene Ltd (BGNE) Earns Outperform Rating from William Blair

The Beigene Ltd (BGNE) Earns Outperform Rating from William Blair

BGNE has been the topic of a number of other research reports. Maxim Group set a $52.00 price target on shares of Beigene and gave the stock a “buy” rating in a report on Thursday, March 2nd. Zacks Investment Research cut shares of Beigene from a “hold” rating to a “sell” rating in a report on Monday, March 27th.

Beigene Ltd (NASDAQ:BGNE)‘s stock had its “outperform” rating restated by analysts at William Blair in a note issued to investors on Thursday.

Beigene (BGNE) opened at 41.01 on Thursday. The stock has a 50 day moving average price of $38.34 and a 200 day moving average price of $35.54. The firm’s market cap is $1.63 billion. Beigene has a 52-week low of $24.53 and a 52-week high of $42.09. Beigene (NASDAQ:BGNE) last posted its quarterly earnings results on Wednesday, March 22nd. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.19. The company had revenue of $1 million for the quarter, compared to the consensus estimate of $3.75 million. The company’s revenue for the quarter was down 78.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($3.05) earnings per share. Equities analysts predict that Beigene will post ($4.97) earnings per share for the current fiscal year.

Beigene (BGNE) opened at 41.01 on Thursday. The stock has a 50 day moving average price of $38.34 and a 200 day moving average price of $35.54. The firm’s market cap is $1.63 billion. Beigene has a 52-week low of $24.53 and a 52-week high of $42.09. In related news, CEO John Oyler sold 36,149 shares of Beigene stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $40.47, for a total value of $1,462,950.03. Following the sale, the chief executive officer now owns 147,440 shares of the company’s stock, valued at approximately $5,966,896.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Xiaodong Wang sold 36,892 shares of Beigene stock in a transaction that occurred on Friday, March 10th. The stock was sold at an average price of $39.89, for a total transaction of $1,471,621.88. Following the completion of the sale, the director now directly owns 150,657 shares in the company, valued at approximately $6,009,707.73. The disclosure for this sale can be found here. Insiders sold a total of 169,248 shares of company stock worth $6,622,132 in the last ninety days.

Large investors have recently bought and sold shares of the company. Morgan Stanley boosted its stake in Beigene by 58.8% in the first quarter. Morgan Stanley now owns 5,795 shares of the company’s stock worth $212,000 after buying an additional 2,146 shares during the period. Renaissance Technologies LLC bought a new stake in Beigene during the first quarter worth approximately $238,000. Airain ltd bought a new stake in Beigene during the first quarter worth approximately $320,000. Geode Capital Management LLC bought a new stake in Beigene during the first quarter worth approximately $345,000. Finally, ProShare Advisors LLC boosted its stake in Beigene by 42.0% in the first quarter. ProShare Advisors LLC now owns 9,872 shares of the company’s stock worth $361,000 after buying an additional 2,918 shares during the period. 33.01% of the stock is currently owned by institutional investors. Beigene Company Profile

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:BGNE”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment